Study on pulmonary parenchymal destruction in asthma
Conditions
Interventions
None listed
Sponsors
Ministry of Health, Labour and Welfare
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have undergone a lung resection of more than one area due to local lesions such as lung cancer between 2006 and November 30, 2021 at the Department of Respiratory Surgery, Hokkaido University Hospital will be eligible for this study. (1) Patients who have no respiratory disease other than the primary disease of surgery, or who have asthma or COPD as a complication. (2) Those who have given their free and voluntary consent to participate in this study, or those who have not received any refusal from the research subjects or those who are considered to represent the will and interests of the research subjects with regard to participation in this study. Translated with DeepL
Exclusion criteria
Exclusion criteria: 1 Those who have a complication of respiratory disease other than the present illness of surgery, asthma, or COPD. 2 Those deemed inappropriate as subjects by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT pulmonary parenchymal destruction index (Exponent D, low attenuation area percent), pathological index (alveolar space length (mean linear intercept), number of alveolar attachments, number of terminal bronchioles) in resected lung specimens | — |
Secondary
| Measure | Time frame |
|---|---|
| Exploratory evaluation using mRNA microarray, Pulmonary elastic fiber-related factors including collagen I, collagen III, fibronectin, matrix metalloproteinase (MMP)-1,MMP-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP) | — |
Countries
Japan
Contacts
Public ContactKaoruko Shimizu
Hokkaido University Graduate School of Medicine, School of Medicine, Respiratory Medicine
Outcome results
None listed